u/15xorbust

$APLD Encouraging details on Delta Forge 2, where the tenant is $META, from the Brookwood town hall.

Management expects 12 to 16 months of construction for the 210 MW campus and outlined the investment split: roughly $800M from the tenant (which we now know is $META from the public filings) and just under $2.5B from $APLD

Permit applications have been submitted and are under city review. Power would come from a nearby substation, with APLD paying for the improvements needed to serve the site.

As expected, community opposition was
insignificant and more than half of the hundreds of seats in this meeting for the public were empty.

This gives us a clearer picture of the construction plan, investment and power arrangements. Approvals from this town that is supportive of the project are still pending, but this article does not confirm a delay or announce a revised operating date.

Source: Tuscaloosa Thread, Oct. 2, 2026:

https://tuscaloosathread.com/applied-digital-brookwood-town-hall/

$CABA presented very encouraging rese-cel results in myasthenia gravis at the AANEM Annual Meeting, Sept. 29 on Oct. 2.

The headline: 10 of 13 hard-to-treat MG patients had meaningful improvement after ONE infusion of rese-cel while OFF their non-steroid immunomodulatory drugs. Nine of those 10 were also off steroids or tapering them. Chemotherapy preconditioning was administered prior to rese-cel.

The improvement was substantial. Among patients who had not required rescue treatment and had reached each follow-up point, average MG-ADL scores improved 7.4 points at 12 weeks (n=11) and 9.8 points at 24 weeks (n=4). The smaller n=4 simply reflects how many patients had reached 24 weeks with data available at the cutoff.

Safety also looked encouraging as only 2 of 13 had CRS, both low-grade, and no ICANS was reported. Very different safety profile than the 2 big pharma CAR-at trials that were paused.

Still a small early-stage study, but 10 of 13 refractory MG patients improving while off their immunomodulatory drugs after a single infusion is a very encouraging signal for rese-cel.

For investors, the key catalyst now is more patients plus longer follow up. If these results hold up, the $CABA stock price should rocket.

To me anyway, nothing has changed with the upward trajectory of the company and rese-cel and the current share price is a bargain - at or near the 52 week low and an opportunity to add shares cheaply.

NeurologyLive:
https://www.neurologylive.com/view/single-infusion-rese-cel-yields-meaningful-responses-off-immunomodulators-phase-1-2-reset-mg-trial

Yesterday, YouTuber Ross Givens falsely reported in a video predicting the downfall of CRWV and companies who do business with it, that APLD’s backlog is only $16 billion and that $11 billion of it is from CRWV. Over 17,000 people so far have watched the video.

Of course that is false.

APLD’s backlog is a whopping $36 billion - over double Ross’s claim - and $CRWV’s actual size in it is 2/3 smaller than Ross’s claim. That is more than any other of the emerging collocation datacenter providers such as WULF, CIFR, GLXY, etc.

Even worse, I have posted a corrective comment about the proper $36 billion backlog on Givens’ YouTube page with cites to the SEC filing and the comment has been promptly deleted.

Ross appears not to know or flat out ignores that besides having ORCL as a $5 billion tenant (at Polaris Forge 2) and CRWV as an $11 billion tenant (at Polaris Forge 1), APLD has also signed $20 billion of leases across three additional data centers (Polaris Forge 3, Delta Forge 1 and Delta Forge 2) with one of the top 4 hyperscalers: Google, Microsoft, Amazon or Meta.

Indeed, APLD’s FY2026 Form 10-K expressly states that, as of May 31, 2026, APLD had approximately $36.2 billion of contracted revenue across five campuses and 1,410 MW of contracted critical IT load:

https://www.sec.gov/Archives/edgar/data/1144879/000114487926000048/apld-20260531.htm?utm_source=chatgpt.com

I hope whomever Ross uses to do his research will get a talking to so this kind of huge mistake about APLD does not recur. I was a Ross fan so I was not happy to see this mistake. And appalled he deleted that corrective comment.

A real man with integrity would admit the mistake and correct it.

The false statement appears at about 8:10 in the video.

Legally, the comment is defamatory as slander as it is a false statement of fact - not opinion - that has the effect of injuring APLD’s business reputation. As such, it enjoys no constitutional protection.

Under the law, everyone is entitled to their own opinion. But posting false statements of fact enjoys no such protection. And the statement that APLD’s backlog is $16 billion and CRWV is a full $11 billion of a $16 billion backlog (that is about 2/3 of all the backlog to make it look like APLD is far more dependent on CRWV than it is) is a false statement of fact - not opinion.

https://youtu.be/7zixcfSGzqM?is=YuY--w6tuFRDxT-q

Above, I found screenshotted all CABA’s abstracts it will present in less than 2 weeks at the EULAR conference in London published on EULAR’s website in a 2500 page compendium of abstracts for the conference. Link below.

The two big most important ones concern the Phase 1/2 results of safety and efficacy of RESE-CEL in severe refractory SLE and lupus nephritis and in severe refractory systemic sclerosis (scleroderma). Results for lupus and lupus nephritis were excellent. Same with scleroderma, where all 6 patients showed clinical improvement. The myositis results showed RESE-CEL very effective against one of the disease’s forms. Less so against others.

There was one Grade 4 ICANS event (a serious neurological complication) in a Lupus Nephritis patient (1 of 9 Lupus patients and 1 of 5 LN patients) that was traced to a hidden infection and that was resolved and one Grade 3 ICANS event in one of the six SSc patients. Both were resolved. Two additional serious adverse events among the 6 SSc patients. No serious adverse events among the 13 myositis patients.

What follows below is my longer layman’s explanation that I prepared for friends and family as many are invested in CABA with collectively, millions of dollars.

My takeaway from the results of the RESET trial on SLE and Lupus Nephritis.

Results were very good for severe refractory lupus and lupus nephritis. 9 patients were treated, 5 with non-kidney lupus and 4 with lupus nephritis. Among the non-kidney lupus patients, 3 of 4 patients achieved DORIS remission, meaning their lupus became clinically quiet by a strict remission standard. Disease activity scores improved meaningfully, and key lupus blood markers also moved in the right direction.

The kidney results were also solid: 3 of 4 lupus nephritis patients showed renal responses, including one complete renal response, one partial response with major proteinuria (protein in urine) reduction, and one patient with biopsy evidence of kidney improvement. Importantly, patients improved after stopping their usual lupus immune drugs, supporting the idea that RESE-CEL may “reset” part of the immune system rather than just suppress it.

My take on the result of the RESET Phase 1/2 trial for scleroderma-great results on efficacy.

All 6 patients showed meaningful improvement on a standard scleroderma response scale. Several had stronger responses showing improvement in skin and overall disease activity. Some patients also showed stabilization or improvement in lung function tests, important because lung disease is one of the most serious complications of scleroderma.

The study also found biological evidence that the therapy was doing what it was designed to do. The engineered CAR-T cells expanded in the body and wiped out most circulating B cells. When B cells later returned, they mostly looked like “new” immature B cells rather than the older, potentially disease-driving ones.

Safety in the SSc trial was mixed. Three of the six patients had more serious safety complications.

The patients were all pretty sick to begin with and all issues were resolved. There was 1 grade 3 ICANS,
1 case of neutropenic fever and 1 case of hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines. 3 cases of CRS nine above grade 2.

Neutropenic fever is a known complication of CAR-T especially where, as here, the patients received chemotherapy preconditioning which suppresses the immune system. In layman’s term’s neutropenic fever means the patient’s immune defenses are temporarily wiped down to very low levels, and they developed a fever that doctors assume could represent a serious infection until proven otherwise. Here the patient’s condition was resolved.

In layman’s terms, hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines means the patient was was likely over-sedated, their breathing became inadequate, carbon dioxide built up, and that excess CO₂ impaired their brain function. Again this patient’s condition was resolved.

Still, me, the safety complications indicate that may be difficult to infuse RESE-CEL to SSc patients in outpatient settings. This is the single biggest Achilles heel in the results.

My takeaway from the RESET Myositis Phase 1/2 Results

The CABA myositis study tested RESE-CEL in 13 patients with severe autoimmune muscle diseases that had not responded well to standard treatments.

These diseases included dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy.

In plain English, these are conditions where the immune system attacks the muscles (and sometimes the skin or lungs) causing weakness, inflammation, fatigue, pain, and potentially serious organ complications.

The study demonstrated that RESE-CEL performed very well against dermatomyositis. Most patients with dermatomyositis or antisynthetase syndrome improved even after stopping many of their regular immune-suppressing medications, and all of the dermatomyositis patients maintained their responses through the latest follow-up. Some patients were able to stay on little or no steroid treatment.

The study also showed strong biological evidence that the RESE-CEL therapy was working as intended. After infusion, the engineered CAR-T cells expanded in the body and sharply reduced B cells, which are immune cells believed to help drive autoimmune disease. When B cells later returned, they mostly looked like newly formed “naive” B cells rather than older immune cells that may have been programmed to attack the body. In layman’s terms, the treatment appeared to partially reboot the immune system. Safety results were encouraging overall, with only mild cytokine release syndrome (CRS) seen in a few patients and no major neurologic toxicity in this study. However, the responses were not equally strong across all myositis types. Dermatomyositis looked best, while antisynthetase syndrome and necrotizing myopathy showed more mixed or less durable results.

Overall these results are excellent and show that RESE-CEL appears to be effective in treating a number of very serious and often fatal autoimmune conditions that often lack effective treatments.

Should be very good for the stock although I expect some questions over the 2 ICANS events (which are common in CAR-T in cancer treatment so doctors know how to treat them). And the two other serious reactions in the SSc trial.

Besides the link, you can also find them by googling 2026 EULAR abstracts. Once you are in the 2500 page compendium of abstracts, you can word search. I found these by using the term Cabaletta Bio.

Link: https://eular.sharepoint.com/sites/AbstractBookletPublication/Shared%20Documents/Forms/AllItems.aspx?viewid=5e3eed70%2Db3f2%2D4558%2Da043%2D3b9d44689e76\\\&id=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents%2FEULAR%202026%20Abstract%20Book%20%28pre%2DCongress%29%2Epdf\\\&parent=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents by

CABA abstracts for the upcoming EULAR conference are now published and online.

Screenshots of all the abstracts here.

This morning, I found CABA’s abstracts it will present in 2 weeks at the EULAR conference in London published on EULAR’s website in a 2500 page compendium of abstracts for the conference. Link below.

The two big most important ones concern the Phase 1/2 results of safety and efficacy of RESE-CEL in severe refractory SLE and lupus nephritis and in severe refractory systemic sclerosis (scleroderma). Results for lupus and lupus nephritis were excellent. Same with scleroderma, where all 6 patients showed clinical improvement. The myositis results showed RESE-CEL very effective against one of the disease’s forms. Less so against others.

There was one Grade 4 ICANS event (a serious neurological complication) in a Lupus Nephritis patient (1 of 9 Lupus patients and 1 of 5 LN patients) that was traced to a hidden infection and that was resolved and one Grade 3 ICANS event in one of the six SSc patients. Both were resolved. No serious adverse events among the 13 myositis patients.

What follows below is my longer layman’s explanation that I prepared for friends and family as many are invested in CABA.

My takeaway from the results of the RESET trial on SLE and Lupus Nephritis.

Results were very good for severe refractory lupus and lupus nephritis. 9 patients were treated, 5 with non-kidney lupus and 4 with lupus nephritis. Among the non-kidney lupus patients, 3 of 4 patients achieved DORIS remission, meaning their lupus became clinically quiet by a strict remission standard. Disease activity scores improved meaningfully, and key lupus blood markers also moved in the right direction.

The kidney results were also solid: 3 of 4 lupus nephritis patients showed renal responses, including one complete renal response, one partial response with major proteinuria (protein in urine) reduction, and one patient with biopsy evidence of kidney improvement. Importantly, patients improved after stopping their usual lupus immune drugs, supporting the idea that RESE-CEL may “reset” part of the immune system rather than just suppress it.

CABA may take on the result of the RESET Phase 1/2 trial for scleroderma-great results on efficacy.

All 6 patients showed meaningful improvement on a standard scleroderma response scale. Several had stronger responses showing improvement in skin and overall disease activity. Some patients also showed stabilization or improvement in lung function tests, important because lung disease is one of the most serious complications of scleroderma.

The study also found biological evidence that the therapy was doing what it was designed to do. The engineered CAR-T cells expanded in the body and wiped out most circulating B cells. When B cells later returned, they mostly looked like “new” immature B cells rather than the older, potentially disease-driving ones.

Safety in the SSc trial was mixed. The patients were all pretty sick to begin with and all issues were resolved. There was 1 grade 3 ICANS,
1 case of neutropenic fever and 1 case of hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines. 3 cases of CRS.

Neutropenic fever is a known complication of CAR-T especially where, as here, the patients received chemotherapy preconditioning which suppresses the immune system. In layman’s term’s neutropenic fever means the patient’s immune defenses are temporarily wiped down to very low levels, and they developed a fever that doctors assume could represent a serious infection until proven otherwise. Here the patient’s condition was resolved.

In layman’s terms, hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines means the patient was was likely over-sedated, their breathing became inadequate, carbon dioxide built up, and that excess CO₂ impaired their brain function. Again this patient’s condition was resolved.

My takeaway from the RESET Myositis Phase 1/2 Results

The CABA myositis study tested RESET-CEL in 13 patients with severe autoimmune muscle diseases that had not responded well to standard treatments.

These diseases included dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy.

In plain English, these are conditions where the immune system attacks the muscles (and sometimes the skin or lungs) causing weakness, inflammation, fatigue, pain, and potentially serious organ complications.

The study demonstrated that RESE-CEL performed very well against dermatomyositis. Most patients with dermatomyositis or antisynthetase syndrome improved even after stopping many of their regular immune-suppressing medications, and all of the dermatomyositis patients maintained their responses through the latest follow-up. Some patients were able to stay on little or no steroid treatment.

The study also showed strong biological evidence that the RESE-CEL therapy was working as intended. After infusion, the engineered CAR-T cells expanded in the body and sharply reduced B cells, which are immune cells believed to help drive autoimmune disease. When B cells later returned, they mostly looked like newly formed “naive” B cells rather than older immune cells that may have been programmed to attack the body. In layman’s terms, the treatment appeared to partially reboot the immune system. Safety results were encouraging overall, with only mild cytokine release syndrome (CRS) seen in a few patients and no major neurologic toxicity in this study. However, the responses were not equally strong across all myositis types. Dermatomyositis looked best, while antisynthetase syndrome and necrotizing myopathy showed more mixed or less durable results.

Overall these results are excellent and show that RESE-CEL appears to be effective in treating a number of very serious and often fatal autoimmune conditions that often lack effective treatments.

Should be very good for the stock although I expect some questions over the 2 ICANS events (which are common in CAR-T in cancer treatment so doctors know how to treat them).

Note that this board only allows you to post one picture and none in the comments so I can’t post all of the screenshots of the results. Besides the link, you can also find them by googling 2026 EULAR abstracts. Once you are in the 2500 page compendium of abstracts, you can word search. I found these by using the term Cabaletta Bio.

Link: https://eular.sharepoint.com/sites/AbstractBookletPublication/Shared%20Documents/Forms/AllItems.aspx?viewid=5e3eed70%2Db3f2%2D4558%2Da043%2D3b9d44689e76\&id=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents%2FEULAR%202026%20Abstract%20Book%20%28pre%2DCongress%29%2Epdf\&parent=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents by

CABA Big news. CABA abstracts for the upcoming EULAR conference are now published and online.

Screenshots of all the abstracts here.

This morning, I found CABA’s abstracts it will present in 2 weeks at the EULAR conference in London published on EULAR’s website in a 2500 page compendium of abstracts for the conference. Link below.

The two big most important ones concern the Phase 1/2 results of safety and efficacy of RESE-CEL in severe refractory SLE and lupus nephritis and in severe refractory systemic sclerosis (scleroderma). Results for lupus and lupus nephritis were excellent. Same with scleroderma, where all 6 patients showed clinical improvement. The myositis results showed RESE-CEL very effective against one of the disease’s forms. Less so against others.

There was one Grade 4 ICANS event (a serious neurological complication) in a Lupus Nephritis patient (1 of 9 Lupus patients and 1 of 5 LN patients) that was traced to a hidden infection and that was resolved and one Grade 3 ICANS event in one of the six SSc patients. Both were resolved.

My takeaway from the results of the RESET trial on SLE and Lupus Nephritis.

Results were very good for severe refractory lupus and lupus nephritis. 9 patients were treated, 5 with non-kidney lupus and 4 with lupus nephritis. Among the non-kidney lupus patients, 3 of 4 patients achieved DORIS remission, meaning their lupus became clinically quiet by a strict remission standard. Disease activity scores improved meaningfully, and key lupus blood markers also moved in the right direction.

The kidney results were also solid: 3 of 4 lupus nephritis patients showed renal responses, including one complete renal response, one partial response with major proteinuria (protein in urine) reduction, and one patient with biopsy evidence of kidney improvement. Importantly, patients improved after stopping their usual lupus immune drugs, supporting the idea that RESE-CEL may “reset” part of the immune system rather than just suppress it.

CABA may take on the result of the RESET Phase 1/2 trial for scleroderma-great results on efficacy.

All 6 patients showed meaningful improvement on a standard scleroderma response scale. Several had stronger responses showing improvement in skin and overall disease activity. Some patients also showed stabilization or improvement in lung function tests, important because lung disease is one of the most serious complications of scleroderma.

The study also found biological evidence that the therapy was doing what it was designed to do. The engineered CAR-T cells expanded in the body and wiped out most circulating B cells. When B cells later returned, they mostly looked like “new” immature B cells rather than the older, potentially disease-driving ones.

Safety in the SSc trial was mixed. The patients were all pretty sick to begin with and all issues were resolved. There was 1 grade 3 ICANS,
1 case of neutropenic fever and 1 case of hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines. 3 cases of CRS.

Neutropenic fever is a known complication of CAR-T especially where, as here, the patients received chemotherapy preconditioning which suppresses the immune system. In layman’s term’s neutropenic fever means the patient’s immune defenses are temporarily wiped down to very low levels, and they developed a fever that doctors assume could represent a serious infection until proven otherwise. Here the patient’s condition was resolved.

In layman’s terms, hypercapnic respiratory failure with encephalopathy in the setting of multiple sedating medicines means the patient was was likely over-sedated, their breathing became inadequate, carbon dioxide built up, and that excess CO₂ impaired their brain function. Again this patient’s condition was resolved.

My takeaway from the RESET Myositis Phase 1/2 Results

The CABA myositis study tested RESET-CEL in 13 patients with severe autoimmune muscle diseases that had not responded well to standard treatments.

These diseases included dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy.

In plain English, these are conditions where the immune system attacks the muscles (and sometimes the skin or lungs) causing weakness, inflammation, fatigue, pain, and potentially serious organ complications.

The study demonstrated that RESE-CEL performed very well against dermatomyositis. Most patients with dermatomyositis or antisynthetase syndrome improved even after stopping many of their regular immune-suppressing medications, and all of the dermatomyositis patients maintained their responses through the latest follow-up. Some patients were able to stay on little or no steroid treatment.

The study also showed strong biological evidence that the RESE-CEL therapy was working as intended. After infusion, the engineered CAR-T cells expanded in the body and sharply reduced B cells, which are immune cells believed to help drive autoimmune disease. When B cells later returned, they mostly looked like newly formed “naive” B cells rather than older immune cells that may have been programmed to attack the body. In layman’s terms, the treatment appeared to partially reboot the immune system. Safety results were encouraging overall, with only mild cytokine release syndrome (CRS) seen in a few patients and no major neurologic toxicity in this study. However, the responses were not equally strong across all myositis types. Dermatomyositis looked best, while antisynthetase syndrome and necrotizing myopathy showed more mixed or less durable results.

Overall these results are excellent and show that RESE-CEL appears to be effective in treating a number of very serious and often fatal autoimmune conditions that often lack effective treatments.

Should be very good for the stock although I expect some questions over the 2 ICANS events (which are common in CAR-T in cancer treatment so doctors know how to treat them).

Link: https://eular.sharepoint.com/sites/AbstractBookletPublication/Shared%20Documents/Forms/AllItems.aspx?viewid=5e3eed70%2Db3f2%2D4558%2Da043%2D3b9d44689e76\&id=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents%2FEULAR%202026%20Abstract%20Book%20%28pre%2DCongress%29%2Epdf\&parent=%2Fsites%2FAbstractBookletPublication%2FShared%20Documents

$CMPX amended its Form 4 filing yesterday to reflect these were code P transactions - open market purchases that company had originally erroneously misreported as Code A transactions - which would have been stock grants. The green footnotes in both Amended Form 4s explains that the amendment was indeed to correct that coding error and report these as the open market common stock purchases that they were.

This is very significant because the company is about to enter discussions with the FDA to approve its new second line chemotherapy drug tovecimig (CTX-009)
for bile duct cancer.

And the General Counsel who bought 25K shares of company stock is the company’s point person in getting FDA approval for its new chemotherapy drug as a second line treatment for bile duct cancer - a $1 billion market.

The stock plunged over 70 percent this week (from $7 to $1.70) after an administration error in its phase 3 clinical trial destroyed the reliability of its Overall Survival endpoint.

The doctors conducting the study contaminated the control group by crossing some of them over who had taken the control agent paclitaxel and then gave them the company’s study drug tovecemig. Those crossover patients lived twice as long on average as the control arm patients who did not take the study drug (12 vs 6 months).

Because there is no second line therapy for bile duct cancer the FDA will likely approve the drug. The study showed good improvement in progression free survival time and the crossover group lived twice as long. The study did not meet the overall survival endpoint because of the crossover which ruined the data in the control arm.

I found the key abstract that CABA will be presenting at the May 11-15 annual meeting of the ASGCT and attached my scans of it from my screenshots. This is buried in the 3500 pages of abstracts on the ASGCT website - linked below.

In this one $CABA provides data for four patients with pemphigus vulgaris who received res-cel with at least 12 week of follow up.

Crucially, these 4 patients DID NOT receive the standard lymphodepleting chemotherapy.

The abstract concluded that the 4 patients experienced rapid clinical improvement, even without the preconditioning.

The abstract report safety was excellent. That there was no dose limiting toxicity or ICANS. One patient experienced grade one cytokine release syndrome 14 days post infusion that was resolved following antipyretics and tocilizumab. Three of four patients had full B cell depletion and all 4 had clinically meaningful reductions in PDAI activity scores.

This is a very significant result and is new data. And we have it early.

https://download.asgct.org/2026ASGCTAbstractPublication.pdf?\\\_gl=1\\\*1v2whkn\\\*\\\_ga\\\*MTI4NDM5NDkxNy4xNzc3NDU5MjE1\\\*\\\_ga\\\_Q37QKR6TCJ\\\*czE3Nzc0NTkyMTQkbzEkZzAkdDE3Nzc0NTkyMTQkajYwJGwwJGgw\\\*\\\_gcl\\\_au\\\*MTIwNjA4MDkyNy4xNzc3NDU5MjE0

I found the key abstract that CABA will be presenting at the May 11-15 annual meeting of the ASGCT and attached my scans of it from my screenshots. This is buried in the 3500 pages of abstracts on the ASGCT website - linked below.

This is the one where they provide data for four patients with pemphigus vulgaris who received res-cel with at least 12 week of follow up.

Crucially, these 4 patients DID NOT receive the standard lymphodepleting chemotherapy.

The abstract concluded that the 4 patients experienced rapid clinic improvement, even without the preconditioning.

The abstract report safety was excellent. That there was no dose limiting toxicity or ICANS. One patient experienced grade one cytokine release syndrome 14 days post infusion that was resolved following antipyretics and tocilizumab. Three of four patients had full B cell depletion and all 4 had clinically meaningful reductions in PDAI activity scores.

This is a very significant result and is new data. And we have it early!

https://download.asgct.org/2026ASGCTAbstractPublication.pdf?\_gl=1\*1v2whkn\*\_ga\*MTI4NDM5NDkxNy4xNzc3NDU5MjE1\*\_ga\_Q37QKR6TCJ\*czE3Nzc0NTkyMTQkbzEkZzAkdDE3Nzc0NTkyMTQkajYwJGwwJGgw\*\_gcl\_au\*MTIwNjA4MDkyNy4xNzc3NDU5MjE0